Dynavax Technologies (Dynavax Technologies) Debt-to-Equity : 0.41 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Debt-to-Equity?

Dynavax Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.5 Mil. Dynavax Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $252.4 Mil. Dynavax Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $622.1 Mil. Dynavax Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.41.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dynavax Technologies's Debt-to-Equity or its related term are showing as below:

DVAX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 1.16 Max: 26.11
Current: 0.41

During the past 13 years, the highest Debt-to-Equity Ratio of Dynavax Technologies was 26.11. The lowest was 0.10. And the median was 1.16.

DVAX's Debt-to-Equity is ranked worse than
59.58% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs DVAX: 0.41

Dynavax Technologies Debt-to-Equity Historical Data

The historical data trend for Dynavax Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Debt-to-Equity Chart

Dynavax Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

26.11

3.71

1.16

0.44

0.41

Dynavax Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.44	0.46	0.45	0.43	0.41

Competitive Comparison of Dynavax Technologies's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dynavax Technologies's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Debt-to-Equity falls into.

Dynavax Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dynavax Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.496	+	252.418)	/	622.072
	=	0.41

Dynavax Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.496	+	252.418)	/	622.072
	=	0.41

Dynavax Technologies (NAS:DVAX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dynavax Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dynavax Technologies (Dynavax Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

DYF1:Germany

Address

2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608

Website

https://www.dynavax.com

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Executives

Robert Janssen	officer: Chief Medical Officer and VP	C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
David F Novack	officer: Senior Vice President	39 YORKSHIRE DR, OAKLAND CA 94618
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Justin Burgess	officer: Principal Accounting Officer	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Ryan Spencer	officer: Co-President and Senior VP	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Elaine D Sun	director	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald	officer: SVP and CFO	100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips	director	C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman	officer: Chief Science Officer and VP	C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach	officer: VP, CBO, and General Counsel	1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063